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CREB = cAMP responsive element binding protein; IL = interleukin; LPS = lipopolysaccharide; MAO = monamine oxidase; NF-κB = nuclear factor-
κB; NO = nitric oxide; PBMC = peripheral blood mononuclear cell; PKA = protein kinase A; ROS = reactive oxygen species; SNS = sympathetic
nervous system; TNF = tumour necrosis factor.
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Introduction
The challenge to the immune system that occurs in
endotoxaemia involves stimulation of immune cells to produce
large amounts of inflammatory cytokines (e.g. IL-1, IL-6 and
tumour necrosis factor [TNF]-α). These mediators stimulate
both the hypothalamic–pituitary–adrenal axis and the
systemic–adrenomedullary sympathetic nervous system
(SNS). Consequently, catecholamines are released from
preganglionic  efferent and postganglionic SNS fibres,
innervating a wide range of target organs and thereby
regulating endotoxin-induced alterations in vascular
resistance and tone, tissue perfusion, cardiac and renal
function, and hormone release. Although dopamine is also
released, noradrenaline (norepinephrine) and adrenaline
(epinephrine) appear to be the principal neurotransmitters in
this respect. In early and late stages of severe inflammation,
catecholamine production is significantly increased [1].
Nevertheless, it must be noted that circulating
catecholamines are poor markers of SNS activation during
acute stress, such as occurs in sepsis [2].
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Abstract
Large quantitaties of inflammatory mediators are released during the course of endotoxaemia. These
mediators in turn can stimulate the sympathetic nervous system (SNS) to release catecholamines,
which ultimately regulate inflammation-associated impairment in tissue perfusion, myocardial
impairment and vasodilatation. Treatment of sepsis is based on surgical and/or antibiotic therapy,
appropriate fluid management and application of vasoactive catecholamines. With respect to the
latter, discussions on the vasopressor of choice are ongoing. Over the past decade dopamine has
been considered the ‘first line’ vasopressor and is frequently used to improve organ perfusion and
blood pressure. However, a growing body of evidence indicates that dopamine has deleterious side
effects; therefore, its clinical relevance seems to be more and more questionable. Nevertheless, it has
not been convincingly demonstrated that other catecholamines are superior to dopamine in this
respect. Apart from its haemodynamic action, dopamine can modulate immune responses by
influencing the cytokine network. This leads to inhibition of expression of adhesion molecules,
inhibition of cytokine and chemokine production, inhibition of neutrophil chemotaxis and disturbed T-
cell proliferation. In the present review we summarize our knowledge of the immunomodulatory
effects of dopamine, with an emphasis on the mechanisms by which these effects are mediated.
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Apart from their haemodynamic effects, circulating catechol-
amines themselves can modulate the cytokine network and
thereby regulate both suppressive and stimulatory effects on
immune responses. Whereas stimulation of α-adreno-
receptors is associated with induction of TNF-α or IL-1 in
monocytes,  β-adrenergic receptor stimulation is commonly
regarded to mediate anti-inflammatory effects (i.e. inhibition of
TNF-α, IL-1, IL-6 and concomitant induction of IL-10
production) [3].
Dopamine synthesis is induced rapidly under inflammatory
conditions. Serum dopamine concentrations are further
increased by therapeutic intervention with dopamine. The
effects of low-dose treatment (i.e. up to 3 µg/kg per min) are
mediated primarily via dopaminergic receptors. Their activation
results in inhibition of platelet aggregation [4], induction of
vasodilatation in renal, mesenteric, cerebral and coronary
vessels, as well as increased systemic blood pressure and
flow [5]. Therefore, over the past two decades dopamine has
been considered to be and recommended as the ‘first line’
vasopressor [6]. Several clinical studies have now evaluated
the renoprotective effect of low-dose dopamine treatment.
These data indicate that dopamine may increase urine output
in critically ill patients, but that it neither prevents nor improves
acute renal failure [7]. Similarly, whether dopamine has
beneficial effects on splanchnic blood flow is also a subject of
controversy [8]. In higher concentrations (3–5 µg/kg per min),
dopamine has positive inotropic effects and causes
vasodilatation in the microcirculation via β1 and β2 adrenergic
receptors, respectively [9]. Dopamine concentrations above
5 µg/kg per min induce platelet aggregation and α1 receptor
mediated vasoconstriction, resulting in decreased micro-
vascular blood flow [10].
It must be stressed, however, that the effect of dopamine
might vary from one patient to another and depends on the
state of disease [11]. Thus, in septic patients β-adrenergic
effects might predominate, even at high dopamine concentra-
tions [12]. This is attributed to different haemodynamic and
cardiovascular functions, and to different tissue and body
fluid distributions in these patients. Furthermore, in patients
with hepatic or renal insufficiency, dopamine serum
concentrations may reach even higher levels because of
decreased clearance [13].
In contrast to the well recognized immunomodulatory effects
of noradrenaline and adrenaline, the influence of dopamine on
inflammatory responses are incompletely defined and
controversially discussed. Most of our understanding of the
nonhaemodynamic effects of dopamine comes from studies
performed in the field of Parkinson’s disease [14]. Recent
studies have also indicated that treatment of kidney donors
with dopamine improves long-term graft survival after kidney
transplantation [15], possibly due to induction of antioxidants
such as heme oxygenase 1 [16] or by reducing hypothermic
preservation related transplant injury [17].
To enable a better understanding of the role of dopamine in
modulating inflammatory responses, the present review
summarizes the possible mechanisms of dopamine’s action
(Table 1).
Dopamine: mechanisms of action
Receptor mediated mechanisms
Dopamine induced immunomodulation is dose dependently
mediated by different types of receptors (Table 2): the
dopaminergic D1 (D1/D5) and D2 (D2/D3/D4) receptors, as
well as the α and β adrenergic receptors.
Dopaminergic receptors
Whereas D1 receptors are known to be present on smooth
muscle cells, endothelial cells, platelets, lymphocytes and
natural killer cells [18,19], their presence on monocytes/
macrophages is still questioned. Stimulation of D1 receptors,
as demonstrated by the use of the selective D1 antagonist
SCH 23390 [20], results in activation of adenylate cyclase
and subsequently generation of cAMP, which in turn activates
protein kinase A (PKA) [21]. Activation of cAMP responsive
element binding protein (CREB) and PKA can inhibit
translocation of nuclear factor-κB (NF-κB) by retarding the
degradation of the inhibitor of NF-κB, namely IκB-α [22].
Because NF-κB appears to be among the transcription
factors that have been implicated in the expression of a wide
range of proinflammatory genes, dopamine induced immune
modulation can be explained via this pathway. NF-κB and
CREB compete for the same KIX binding site on the
coactivator molecule CREB-binding protein and are
transcriptionally active if they are bound to CREB-binding
protein only [23]. Therefore, dopamine induced CREB
activation also results in diminished NF-κB dependent
transcription, and hence in an impairment of the inflammatory
response. Similar to D1 receptors, stimulation of D2
receptors, which are expressed on lymphocytes [24],
endothelial cells [20] and platelets [19], leads to generation
of cAMP and inhibits the NF-κB dependent transcription
cascade. However, there are also reports indicating that
stimulation of D2 receptors activates NF-κ B in a time and
dose dependent manner [25].
α and β Adrenergic receptors
Most inflammatory cells express α and  β adrenoreceptors.
Although  α1 adrenoreceptor stimulation does not seem to
play a role in inflammatory responses, activation of α2
receptors has a marked influence on inflammatory cells.
Stimulation of α2 receptors induced the production of a
variety of proinflammatory cytokines (e.g. TNF-α, IL-1 and IL-6)
and anti-inflammatory cytokines (e.g. IL-10). α2 Receptor
mediated cytokine production is regulated via activation of
protein kinase C, phosphorylation of IκB and subsequently
activation of NF-κB [26].
The  β-adrenergic receptors, predominantly β2, are also
coupled to the cAMP–PKA pathway. Hence, stimulation of487
these receptors inhibits the transcription of NF-κB regulated
proinflammatory genes in a manner similar to that described
above [27]. Furthermore, cAMP can also indirectly activate
CCAAT/enhancer binding protein [28], which, together with
CREB/activating transcription factor, is believed to be largely
responsible for β2 adrenoceptor mediated IL-10 production in
monocytes [29].
IL-10 inhibits lipopolysaccharide (LPS) mediated TNF-α
production both in vivo and in vitro [30], and it can therefore
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Table 1
Immunomodulatory effects of dopamine under septic conditions
Influence on Effect Mechanism
Pituitary hormones Prolactin  Suppression Indirectly via nNOS, D2 receptor
Thyroid hormones Suppression D2 receptor
Growth hormones Suppression D2 receptor
Glucocorticoid Induction α2 receptor, D2 receptor
Cytokines IL-10 Induction β receptor, ROS
TNF-α (monocytes, HUVECs) Suppression β receptor, ROS
TNF-α (neutrophils) Suppression D1 receptor
IL-1 Suppression β receptor, ROS
IL-6 (monocytes, HUVECs) Suppression β receptor, ROS
IL-6 (glomerulosa cells) Induction D2 receptor
IL-12 p40 Suppression β receptor
Chemokines IL-8 (HUVEC) Induction  ROS
IL-8 (PTEC) Suppression ROS
Gro-α Suppression ROS
ENA-78 Suppression ROS
Adhesion molecules CD11b/CD18 Suppression ROS
E-selectin Suppression ROS?
ICAM-1 Suppression ROS?
Nitric oxide In HUVECs Suppression ROS
In monocytes Induction β receptor
Apoptosis In neutrophils Induction D1 and β receptor, ROS
In lymphocytes Induction D1 and β receptor, ROS
PLA2 metabolites PAF Suppression ?
Respiratory burst In neutrophils Suppression D1 receptor
HUVEC, human umbilical vein endothelial cell; ICAM, intercellular adhesion molecule; IL, interleukin; nNOS, neuronal nitric oxide synthase; PAF,




Dopamine concentration α1 adrenergic α2 adrenergic β1 adrenergic β2 adrenergic Dopamine D1 Dopamine D2
0–3 µg/kg per min 0 0 + 0 +++ +++
3–5 µg/kg per min + + +++ ++ ++++ ++++
>5 µg/kg per min +++ + +++ + ++++ ++++488
be considered part of a host protective mechanism during
endotoxaemia. However, van der Poll and coworkers [31]
found that in LPS-stimulated blood the increase in IL-10
levels caused by adrenaline only marginally contributed to
concurrent inhibition of TNF-α production. These conclusions
emphasize that the role of IL-10 as a causal factor in
immunosuppression remains controversial.
Oxidative stress
Dopamine also mediates cellular effects, independent of or in
conjunction with receptor activation. The clearance of dopamine
depends in part on its rate of degradation by monamine oxidase
(MAO)-A and MAO-B [32], which catalyzes the oxidative
deamination of dopamine. Hydrogen peroxide (H2O2) is
generated as a consequence of MAO mediated degradation of
dopamine [33]. In the presence of Fe2+ this is further converted
through the Fenton reaction into highly reactive hydroxyl radicals
(HO•). H2O2 and HO• have been found to have both beneficial
and deleterious effects on cells, depending on the
concentration and cellular system in which they were studied.
Reactive oxygen species (ROS) act as intracellular messengers
activating multiple signalling pathways, including activation of c-
Jun N-terminal kinase, extracellular signal regulated kinases, NF-
κB and activator protein-1 [34].
Low concentrations of ROS improve the cellular redox status
by increasing the amount of endogenous antioxidants such as
superoxide dismutase, heme oxygenase 1 and ferritin [35].
However, as a consequence of their aggressive nature, high
concentrations of ROS inevitably result in cytotoxicity and
genotoxicity.
Dopamine can also form reactive metabolites through auto-
oxidation. Because of the unstable nature of the catechol
group, it can be oxidized to reactive quinone molecules,
which themselves exert toxic effects. Although oxidation of
dopamine is primarily mediated via ROS [36], a number of
enzymes are able to catalyze dopamine quinone formation,
including prostaglandin H synthase, xanthin oxidase and
tyrosinase [37]. This auto-oxidation is prevented by
antioxidants (e.g. ascorbic acid) [38]. It has been suggested
that the toxicity of dopamine quinones is mediated via protein
and DNA damage, ultimately leading to apoptosis [39].
Effects of dopamine on the neuroendocrine
system
The production of proinflammatory cytokines and chemokines
by monocytes/macrophages and endothelial cells under
septic conditions is well documented. Severe inflammation is
accompanied by alterations in activity of the neuroendocrine
system. In the early stage of inflammation hormone release is
stimulated, whereas in the late phase its release is
suppressed [40]. Therefore, marked variations in serum
cortisol, thyroid hormone, growth hormone and prolactin
concentrations occur during the course of systemic
inflammation. Dopamine suppresses the release of most if not
all anterior pituitary dependent hormones [41], but at the
same time it stimulates the synthesis of adrenal
glucocorticoids via α2 and D2 receptors [42]. The changes
induced in the hypothalamic–pituitary–adrenal axis by
dopamine when it is administered in the early phase of severe
inflammation are similar to those that occur in the late phase
without dopamine treatment [41].
Bacterial LPS affects pituitary hormone secretion, including
prolactin release, by inducing synthesis and release of
cytokines such as TNF-α [43]. It is now generally accepted
that prolactin can enhance monocyte, and T-cell and B-cell
immune responses under normal conditions, and has
beneficial effects on cell-mediated immunity after haemor-
rhage [44]. Because prolactin is mainly under the inhibitory
control of dopamine, decreased serum prolactin
concentration might lead to compromised immune function
and hence susceptibility to infection [45]. Several studies
have shown that therapeutic intervention with dopamine in
critically ill infants and adults dramatically decreases serum
prolactin concentrations, thereby questioning the use of
dopamine in these patients [46].
Effects of dopamine on the production of
inflammatory mediators
Endothelial cells
The barrier function of endothelial cells is important in
preventing vascular leakage and free migration of
inflammatory cells. During sepsis impairment in barrier
functions allows plasma proteins to enter into the interstitium,
supporting oedema formation. The barrier function is further
impaired by mononuclear cells, which first adhere to the
endothelium and then are triggered to leave the circulation via
migration between endothelial cells. D1 and D2 dopamine
receptors are present on endothelial cells, rendering them
responsive to dopamine. Both in vitro and  in vivo studies
have shown that dopamine inhibits LPS mediated up-
regulation of adhesion molecules expressed on macro-
vascular and microvascular endothelial cells [47], with a
concomitant decrease in neutrophil migration [48].
Interestingly, dopamine has a dual effect on endothelial
chemokine production. Although basal and LPS mediated
production of growth-related-gene α (Gro-α) and epithelial
neutrophil activating protein-78 (ENA-78) are significantly
downregulated by dopamine, the reverse has been found for
IL-8 [47]. This effect is still observed when the cells are
stimulated with LPS for up to 3 hours before dopamine
administration. Neither dopamineric nor adrenergic receptor
antagonist were able to influence this action of dopamine. In
contrast, addition of antioxidants completely prevented the
action of dopamine, suggesting a pivotal role for oxidative
stress. Although addition of H2O2 to microvascular
endothelial cells yielded results similar to those with
dopamine stimulation, neither the MAO inhibitor pargylin nor
the dopamine uptake inhibitor GBR 12909 was able to inhibit
the effects of dopamine.
Critical Care    December 2004 Vol 8 No 6 Beck et al.489
Neutrophils
During inflammatory responses neutrophils are among the
first cell types that leave the microcirculation and enter into
the inflammatory site. Dopamine uptake, storage and
synthesis by these cells have been described [49]. Dopamine
treatment may lead either directly or indirectly to a functional
suppression of neutrophils, which was demonstrated for
transmigration of stimulated neutrophils after dopamine
administration. This was mediated by a decreased neutrophil
adhesion to endothelial cells caused by a reduction in
CD11b/CD18 expression on neutrophils, and by attenuation
of the chemoattractant effect of IL-8 required for trans-
endothelial migration of neutrophils [48]. In addition,
pharmacological concentrations of dopamine induce
apoptosis in neutrophils isolated from healthy volunteers and
reverse delayed apoptosis of neutrophils in septic patients
[50]. These effects are not receptor mediated because the
D1 agonist fenoldopam did not influence neutrophil
behaviour. In contrast, the effects of dopamine on respiratory
burst, phagocytosis [51,52] and TNF-α release are probably
D1 receptor dependent [52].
Monocytes/macrophages
It was shown that macrophages can release or store
dopamine in cytoplasmic vesicles [53], but the presence of
dopaminergic receptors on monocytes/macrophages has not
clearly been demonstrated [54]. During the early phase of
inflammation, cytokines such as TNF-α, IL-1, IL-12 p40 and
IL-6, and chemokines such as IL-8 are highly upregulated in
monocytes/macrophages. Dopamine or dopamine agonists
significantly inhibited this [55]. In accordance with those
findings, treatment with the dopamine antagonist metoclo-
pramide stimulated constitutive and inducible expression of
proinflammatory cytokines in vitro [43], whereas it
suppressed chlorpromazine induced production of the anti-
inflammatory cytokine IL-10 in vivo [56]. The effects of
dopamine on cytokine production are mainly mediated via β
adrenoceptors because the action of dopamine was partly
prevented by propanolol and not influenced by dopaminergic
receptor antagonists [57]. Because propanolol reversed the
effect of dopamine, it has been suggested that receptor
independent mechanisms might also play a role. Dopamine
induced ROS are most likely involved in mediating changes in
monocyte/macrophage phenotype and function [58].
Basal nitric oxide (NO) production by macrophages is not
altered, or only minimally, by dopamine, whereas LPS
induced NO production is strongly increased via β receptor
stimulation [59]. This mechanism might contribute to the
increased NO production found in critically ill patients.
Lymphocytes
Among the catecholamines, adrenaline and noradrenaline are
the ones that have been most extensively investigated for
their regulatory effects on immune responses in lymphocytes,
antigen presenting cells and natural killer cells [60]. The
synthesis and release of dopamine by lymphocytes, as well as
the presence of D1 receptors, suggest regulation of func-
tional activities such as lymphocyte proliferation, differentia-
tion and cytokine production [61]. In vitro experiments with
dopamine or the dopamine receptor agonist bromocriptine
revealed a significant inhibition of lymphocyte proliferation,
which was mediated either by dopaminergic receptors [62]
or by ROS [63]. Furthermore, selective effects on T-cell
mediated immunity (i.e. downregulation of delayed-type
hypersensitivity responses) have also been described [64].
Similarly, in blood of septic patients receiving dopamine, a
decrease in in vitro T-cell proliferation in response to
concanavalin has been observed [46]. In contrast, in vivo
experiments in mice using dopamine or D1 and D2 receptor
agonists showed stimulation of basal B-cell and T-cell
proliferation, and augmented LPS-induced proliferation [65].
These effects may also be indirectly mediated by influencing
the microinvironment and mediator production by accessory
cells [24].
Effects of dopamine on apoptosis
Dopamine is involved in the modulation of apoptosis in both
neuronal and non-neuronal cells. There is evidence that
dopaminergic mechanisms may contribute to neuro-
degeneration in Parkinson’s disease. In striatal neurones
high concentrations of dopamine are proapoptotic; however,
low concentrations of dopamine prevent cell death, possibly
due to the ability of dopamine to affect intracellular oxidative
processes [66]. It is currently believed that excessive oxidant
stress, induced by metabolism of dopamine, plays a major
role in the pathogenesis of the selective nigrostriatal
neuronal loss that occurs in Parkinson’s disease. It was
recently shown that dopamine, in physiological
concentrations, is capable of initiating apoptosis in cultured,
postmitotic sympathetic neurones. Stable transfection of
Bcl-2 in PC-12 pheochromocytoma cells was able to inhibit
dopamine mediated apoptosis [67]. Dopaminergic
modulation of apoptosis has also been investigated in
human peripheral blood mononuclear cells (PBMCs)
obtained from healthy donors. Dopamine treatment at low
concentrations reduced spontaneous apoptosis, whereas
apoptosis was enhanced at higher concentrations. At low
dopamine concentrations this was inhibited by the D1-like
receptor antagonist SCH 23390, but not by the D2-like
receptor antagonists domperidone or haloperidol. At high
concentrations the effect was prevented by the antioxidants
glutathione or N-acetyl-L-cysteine [68]. Dopamine does not
affect the expression of Cu/Zn superoxide dismutase or Bcl-
2 in PBMCs. In human PBMCs, dopamine appears to
promote apoptosis through oxidative mechanisms but it may
also rescue cells from apoptotic death, possibly through
activation of D1-like receptors. Other authors have
suggested that dopamine induced apoptosis in lymphocytes
is mediated by β receptors [69]. The dual effect of dopamine




Because dopamine can have adverse effects on organ
function during septic processes, clinical use of dopamine is
increasingly being questioned. However, clinically relevant
concentrations of dopamine also inhibit inflammation induced
upregulation of cytokines, chemokines and adhesion molecules,
and induce the production of anti-inflammatory mediators.
Because of its immunomodulatory effects, dopamine might
gain a new therapeutic role in the treatment of immunological
dysregulation. To evaluate the immunomodulatory potential of
dopamine, more clinical studies conducted in patients with or
without severe inflammation would be useful.
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